Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
umbilical cord-derived mesenchymal stem cell spheroids (Acibadem University)
- Development stage
- Unknown
- Lead developer
- Acıbadem Üniversitesi
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Ophthalmic
01
Overview
Umbilical cord-derived mesenchymal stem cell (UC-MSC) spheroids are an advanced cell therapy product developed by Acibadem University (Acibadem Labcell) for the treatment of retinitis pigmentosa. The therapy utilizes the paracrine potential of mesenchymal stem cells, which are known to secrete a variety of neurotrophic factors, including brain-derived neurotrophic factor (BDNF) and ciliary neurotrophic factor (CNTF), to support the survival and function of degenerating photoreceptors. By delivering these cells as three-dimensional spheroids into the suprachoroidal space, the treatment aims to provide a sustained release of these factors in close proximity to the retina, potentially slowing the progression of vision loss. This approach leverages the immunomodulatory and anti-apoptotic properties of MSCs to create a more favorable environment for retinal cell survival while minimizing the risks associated with subretinal or intravitreal injections.
- Other names
- UC-MSC spheroidsUmbilical cord-derived mesenchymal stem cells (Acibadem University)umbilical cord-derived mesenchymal stem cells-Acibadem University-retinitis pigmentosa
Beyond the preview
Go deeper on umbilical cord-derived mesenchymal stem cell spheroids (Acibadem University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on umbilical cord-derived mesenchymal stem cell spheroids (Acibadem University).